The earnings call showcased strong financial performance with significant growth in KIMMTRAK sales and global expansion. The company is advancing its pipeline with multiple Phase III trials and early-stage programs. While operating expenses have increased, the overall financial health remains robust, and growth is expected to moderate. The highlights significantly outweigh the lowlights, indicating a positive sentiment.

Company Guidance

During the Immunocore Q2 and first half 2025 earnings call, the company reported a strong start to the year with $192 million in KIMMTRAK revenue, representing a 32% year-over-year growth. KIMMTRAK has been launched in 28 countries and approved in 39, and in Q2 alone, net sales reached $98 million, marking the 13th consecutive quarter of growth. In the U.S., the net revenue was $64 million, a 15% increase from Q2 2024, with a market penetration of around 68%. In Europe, Q2 net revenue was $33 million, reflecting a 115% quarterly growth year-on-year, driven by successful launches in the U.K., Poland, and the Netherlands. The company is also advancing three Phase III clinical trials and plans to file a CTA for their type 1 diabetes autoimmune candidate by year-end. With a strong balance sheet holding $883 million in cash and marketable securities, Immunocore is well-positioned to continue strategic investments across its diversified pipeline.

KIMMTRAK Revenue Growth

Generated $192 million in KIMMTRAK revenue for the first half of 2025, representing 32% growth year-over-year. Q2 net sales reached $98 million, a 30% increase from the previous year and a 4% sequential increase over Q1 2025.

Expansion and Global Reach

KIMMTRAK is launched in 28 countries and approved in 39 globally. Recent successful launches in the UK, Poland, and Netherlands contributed to an exceptional 115% year-on-year growth in European markets.

Strong Financial Position

Net loss reduced from $36 million to $5 million in the first half of the year compared to last year. A strong balance sheet with $883 million in cash and marketable securities.

Pipeline Advancements

Progressing multiple early-stage programs in oncology and infectious diseases. On track to file the CTA for autoimmune candidates in type 1 diabetes by year-end 2025.

Phase III Clinical Trials Progress

Three Phase III clinical trials in progress, including TEBE-AM, the only registrational Phase III trial in adjuvant uveal melanoma setting.

Immunocore Holdings (IMCR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMCR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.24 / -	0.17	―	―	―
Aug 07, 2025	2025 (Q2)	-0.14 / -0.20	-0.23	13.04% (+0.03)
May 07, 2025	2025 (Q1)	-0.38 / 0.10	-0.49	120.41% (+0.59)	―	―
Feb 26, 2025	2024 (Q4)	-0.23 / -0.47	-0.4	-17.50% (-0.07)
Nov 06, 2024	2024 (Q3)	-0.34 / 0.17	0.049	246.94% (+0.12)	―	―
Aug 08, 2024	2024 (Q2)	-0.48 / -0.23	-0.369	37.67% (+0.14)
May 08, 2024	2024 (Q1)	-0.37 / -0.49	-0.43	-13.95% (-0.06)	―	―
Feb 28, 2024	2023 (Q4)	-0.25 / -0.40	-0.63	36.51% (+0.23)
Nov 07, 2023	2023 (Q3)	-0.35 / 0.05	0.137	-64.23% (-0.09)	―	―
Aug 10, 2023	2023 (Q2)	-0.39 / -0.37	-0.172	-114.53% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMCR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$32.10	$31.93	-0.53%
May 07, 2025	$28.06	$29.92	+6.63%
Feb 26, 2025	$29.21	$30.77	+5.34%
Nov 06, 2024	$32.99	$33.51	+1.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Immunocore Holdings (IMCR) report earnings?

Immunocore Holdings (IMCR) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Immunocore Holdings (IMCR) earnings time?

Immunocore Holdings (IMCR) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMCR EPS forecast?

IMCR EPS forecast for the fiscal quarter 2025 (Q3) is -0.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing